Matinas Biopharma Holdings Inc
Research Matinas Biopharma Holdings Inc (MTNB) on Bullrun: market cap USD 1.26M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMTNB
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.26M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 10.61M
- Free cash flow-USD 6.61M
Valuation Snapshot
latest market cap is USD 1.26M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 10.35M | -USD 7.01M | n/a | -2 | USD 4.00M | USD 1.35M | USD 4.83M |
| FY2024 | USD 0 | -USD 24.25M | -USD 15.89M | n/a | -4.98 | USD 7.28M | USD 2.89M | USD 7.59M |
| FY2023 | USD 1.10M | -USD 22.94M | -USD 15.50M | n/a | -5.28 | USD 4.79M | USD 3.56M | USD 19.25M |
| FY2022 | USD 3.19M | -USD 21.00M | -USD 20.05M | n/a | -0.1 | USD 6.83M | USD 4.43M | USD 36.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.26M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.78M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.59M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 46.93M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 108.43M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 218.43M | n/a | n/a | n/a |
About Matinas Biopharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Matinas Biopharma Holdings Inc's market cap?
Matinas Biopharma Holdings Inc's market capitalization is USD 1.26M.
What does Matinas Biopharma Holdings Inc do?
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.